Director, Global Clinical Physician - Early Clinical Development Oncology Bristol Myers SquibbDirector, Global Clinical Physician - Early Clinical Development OncologyBrisbane, CA$308,700–$374,075 / yearDesigns and develops clinical studies and research plans in support of asset strategy with the Early Clinical Development Leadership team; clinical studies include first-in-human Phase I, proof of concept Phase I/II, entry registrational studies, biomarker qualification studies, and/or clinical pharmacology studies. Serves as an independent Medical Monitor for clinical trials from Phase 1 through Proof-of-Concept by: Articulating clinical development strategy, Analyzing, interpreting, and acting on clinical trial data to support development, Serving as principal functional author for Regulatory submission, study reports, and publications.
Clinical Supply Chain Director Exelixis Inc.Clinical Supply Chain DirectorAlameda, CA$164,500–$234,500 / yearOversees activities relating to the labeling, packaging, and distribution plans for each study (e.g., bulk drug products, matching placebo, PK/PD samples, etc.) based on protocol requirements and factors such as regulatory requirements, blinding concerns, ease of handling by the sites and patients, and patient compliance. EDUCATION/EXPERIENCE/KNOWLEDGE & SKILLS: Education/Experience: BS/BA degree in related discipline and a minimum of thirteen years of related experience; or, MS/MA degree in related discipline and a minimum of eleven years of related experience; or, PhD in related discipline and a minimum of eight years of related experience; or, Equivalent combination of education and experience.
New988 Suicide Prevention - Associate Director, Clinical Practice & Quality Contra Costa Crisis Center988 Suicide Prevention - Associate Director, Clinical Practice & QualityWalnut Creek, CA$100,000–$130,000 / yearAssociate Director, Clinical Practice & Quality Contra Costa Crisis Center — Walnut Creek, CA Location: On-site at our Walnut Creek office Status: Exempt Full-Time Reports to: Executive Director Compensation : $100,000 – 130,000 Annually CCCC is a 988 Suicide & Crisis Lifeline center and 211 provider serving Contra Costa County. Our Values Compassion | Integrity | Equity | Collaboration | Excellence We believe every person in crisis deserves dignity, empathy, and skilled support — and that the professionals who provide that support deserve strong leadership, structure, and care.
Director, Clinical Compliance Jade BiosciencesDirector, Clinical ComplianceSan Francisco, CaliforniaRemoteEmbedded within the Development Operations Operational Excellence team, this role functions as an internal GCP compliance leader who partners closely with study teams, vendors, and Quality Assurance (QA) to maintain inspection readiness and operational quality across all clinical programs. Support study teams in identifying and appropriately escalating significant compliance issues, protocol deviations, and site noncompliance, ensuring issues are investigated, documented, and resolved in accordance with regulatory expectations.
Director Clinical Pharmacology & Dmpk Alumis Inc.Director Clinical Pharmacology & DmpkSouth San Francisco, CA$200,000–$240,000 / yearAlumis is seeking a Director of Clinical Pharmacology & DMPK to drive clinical pharmacology strategy and PK/PD modeling for our small-molecule programs in immune-mediated diseases. Specific responsibilities include but are not limited to: Lead clinical pharmacology strategy, dose selection, and PK/PD and biomarker planning across early and late-stage programs.
Medical Director, Clinical Development(Nephrology) Jade BiosciencesMedical Director, Clinical Development(Nephrology)San Francisco, CaliforniaRemote$270,000–$300,000 / yearEducate and advise clinical sites/investigators to support enrollment and optimal study conduct, including presenting at investigator meetings and/or site initiation visits, and serving as the medical point of contact for site staff questions about patient eligibility, and providing input into patient safety assessment and management. Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases.
Senior Director, Clinical Pharmacology And Translational Pk/Pd Vir Biotechnology, Inc.Senior Director, Clinical Pharmacology And Translational Pk/PdSan Francisco, CA$235,500–$329,500 / yearIts clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN dual-masked T-cell engagers across validated targets in solid tumor indications. Work collaboratively with cross-functional teams, including clinical research, clinical operations, biomarkers, bioanalytical, biometrics, CMC, research, and regulatory in support of program advancement.
Associate Director, Clinical Data Management Corcept TherapeuticsAssociate Director, Clinical Data ManagementRedwood City, CA$229,300–$269,800 / yearWith advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease, Corcept is unlocking the power of cortisol modulation to help address some of the most devastating diseases patients face today. The pay range that the Company reasonably expects to pay for this headquarters-based position is $229,300 - $269,800; the pay ultimately offered may vary based on legitimate considerations, including geographic location, job-related knowledge, skills, experience, and education.
Executive Director & Head Clinical Data Management Annexon, Inc.Executive Director & Head Clinical Data ManagementSan Francisco, CARemote$301,500–$330,000 / yearOur novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. Company: At Annexon Biosciences we are a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye.
Director of Quality Assurance, Clinical Caribou Biosciences, Inc.Director of Quality Assurance, ClinicalBerkeley, CA$220,000–$235,000 / yearProvide Clinical Quality Assurance (GCP) strategic and technical leadership and Subject Matter Expertise (SME) to clinical study teams; Partner with the teams to effect appropriate and timely documentation of quality event management, including CAPA plans in support of product pipeline. The successful candidate must have the ability to execute QA tasks independently; effectively represent QA in a GCP, PV, and GLP focused team settings and manage quality related activities related to clinical vendors, investigator sites and regulatory agencies.
Director, Biostatistics, Late Clinical Stage Revolution Medicines, Inc.Director, Biostatistics, Late Clinical StageRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: Playing a critical role as a lead statistician for clinical program(s) and studies in clinical late-stage development and the subject matter expert (SME) in Biostatistics within Quantitative Sciences function, this position is to provide statistical leadership and support for clinical development strategy and clinical studies through product life cycle.
Senior Director, Clinical Development BridgeBio Pharma, Inc.Senior Director, Clinical DevelopmentSan Francisco, CA$340,000–$375,000 / yearThe final salary offered to a successful candidate will depend on several factors that may include but are not limited to the type and length of experience within the job, type, and length of experience within the industry, educational background, location of residence and performance during the interview process. Skill Development & Career Paths: People are part of our growth and success story - from discovery to active drug trials and FDA pipelines, there are endless opportunities for skill development and internal mobility.
Associate Director, Clinical Regulatory Denali TherapeuticsAssociate Director, Clinical RegulatorySouth San Francisco, CA$171,000–$223,000 / yearDevelops, manages, and mentors junior regulatory professionals and contributes to creating a culture regulatory innovation and excellence; leads direct report(s), if applicable, through annual goal setting, growth planning, adherence to company policies, maintains training compliance and provides ongoing feedback on growth, development and areas of improvement. Key Accountabilities/Core Job Responsibilities: Accountable for developing regulatory strategy for complex development programs; leads project teams in implementing and delivering the regulatory strategy across multiple programs/indications and/or programs of increasing complexity.
Director, Clinical Operations Maze TherapeuticsDirector, Clinical OperationsSouth San Francisco, CA$232,000–$283,000 / yearServe as the operational Study Lead for a global pivotal Phase 3 study (North America, South America, Africa, and Europe), maintaining responsibility for successful execution from protocol development and start-up through enrollment, database lock, study closeout, submission support, and inspection readiness. Maintain a continuous state of inspection readiness across the study, including safety reporting, TMF completeness and quality, essential documentation, evidence of vendor oversight, issue and CAPA management, and audit preparedness, in close partnership with Quality Assurance (QA).
Executive Director, Clinical Supply Chain Revolution Medicines, Inc.Executive Director, Clinical Supply ChainRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Senior Medical Director, Early-Stage Clinical Development Revolution Medicines, Inc.Senior Medical Director, Early-Stage Clinical DevelopmentRedwood City, CA$346,000–$397,000 / yearHas demonstrated collaborative behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Early Clinical Development Revolution Medicines, Inc.Executive Director, Early Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, GCP QA (Good Clinical Practice, Quality Assurance) Revolution Medicines, Inc.Executive Director, GCP QA (Good Clinical Practice, Quality Assurance)Redwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Minimum of 15 years of experience in the pharmaceutical or biotechnology industry, including at least 10 years in GCP QA or clinical quality leadership roles, with demonstrated experience leading and hosting regulatory inspections (e.g., FDA BIMO, EMA, MHRA, PMDA).
Medical Director, Early-Stage Clinical Development Revolution Medicines, Inc.Medical Director, Early-Stage Clinical DevelopmentRedwood City, CA$295,000–$339,000 / yearHas demonstrated collaborative behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Clinical Development Revolution Medicines, Inc.Executive Director, Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.